PAKISTAN JOURNAL OF MEDICAL AND HEALTH SCIENCES, cilt.14, sa.4, ss.1389-1391, 2020 (ESCI, Scopus)
Aim: In adults glioblastoma multiforme (GBM) is the deadly and utmost communal brain tumor. GBM has poor
prognosis and the median general endurance hardly surpasses one-year. In this study, we retrospectively
assessed the demographic and clinical characteristics of patients with GBM and to recognize significant
prognostic factors that may be associated with better results in our population.
Material and Methods: The clinicopathological, treatment parameters (ie, chemotherapy, radiotherapy and the
surgical resection extent) and demographic parameters were attained from medical records. SPSS version 23.0
was applied for all statistical analyzes. The overall survival and median progression-free survival was 14.1 and 10
months; correspondingly.
Results: In the subjects with the longest overall survival group, a tumor was found in the frontotemporal area, and
then in the frontal area. In a univariate analysis, age, co-administration of adjuvant temozolomide (TMZ) and
chemoradiotherapy were prognosticators of both overall survival (OS) and progression-free survival (PFS).
Though, in multivariate analysis, radiotherapy and age were important determinants of endurance. Subjects who
received the cyber-knife after relapse had a lengthier operating system.
Conclusion: The patients were retrospectively assessed with GBM in the facility, and the outcomes confirmed
formerly testified factors influencing GBM endurance.